Apatinib Treatment for Advanced Esophagus Cancer

Sponsor
Henan Cancer Hospital
Study ID
NCT03170310
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Esophagus Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.

Study Details

Subject ever received a standard chemotherapy solution progression or recurrence or can't tolerate chemotherapy with advanced esophageal squamous carcinoma.

Key Dates

Start date
Feb 21, 2017
Status verified
May 2017
Primary completion
Feb 21, 2019
Completion
Sep 21, 2019

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib

Primary Outcome Measure

Progress free survival [ Time Frame: 24 months ]

Central Contacts